Cor Pulmonale

Background #

Cor pulmonale is defined as right ventricular (RV) enlargement and/or dysfunction resulting from pulmonary hypertension secondary to diseases of the lung parenchyma, pulmonary vasculature, or chest wall. It specifically excludes RV dysfunction due to left heart disease or congenital heart disease.[1] The condition represents a significant clinical challenge, accounting for approximately 6-7% of all adult heart disease in the United States.[2]

Classification/Types #

Acute Cor Pulmonale: Sudden RV dysfunction, most commonly caused by massive pulmonary embolism or acute respiratory distress syndrome (ARDS). In ARDS, acute cor pulmonale occurs in approximately 22% of patients ventilated with protective strategies and is associated with increased 28-day mortality.[3]

Chronic Cor Pulmonale: Gradual RV remodeling and failure due to long-standing pulmonary hypertension, most frequently from chronic obstructive pulmonary disease (COPD) or interstitial lung diseases (ILD).[1]

Epidemiology #

Prevalence: Cor pulmonale accounts for 6-7% of all types of adult heart disease in the United States, with COPD causing more than 50% of cases.[2][4] The exact prevalence is difficult to determine, as physical examination and routine tests are relatively insensitive for detecting pulmonary hypertension and RV dysfunction.[2]

Sex: More common in men, primarily due to higher COPD prevalence associated with smoking.[1]

Age: Typically affects individuals over 50 years of age, correlating with the progression of chronic lung diseases.[5]

Geographic Variation: The incidence varies widely among countries, depending on air pollution levels, cigarette smoking prevalence, and other risk factors for lung diseases.[2]

Socioeconomic Status: Higher prevalence in lower socioeconomic groups due to poor access to healthcare, higher smoking rates, and increased exposure to indoor and environmental pollutants.[1]

Pathophysiology #

The pathophysiology of cor pulmonale centers on the development of pulmonary hypertension leading to RV dysfunction. Under normal physiologic conditions, the right ventricle pumps against a low-resistance pulmonary circuit, with pulmonary vascular resistance approximately one-tenth that of systemic arteries.[6]

Chronic hypoxemia is the primary driver of increased pulmonary vascular resistance. Prolonged alveolar hypoxia triggers pulmonary arteriolar vasoconstriction—a physiologic mechanism that becomes maladaptive in chronic lung disease—leading to smooth muscle proliferation and vascular remodeling in small pulmonary arteries.[7] Hypoxemia also disrupts vascular mediator balance: nitric oxide (a vasodilator) production decreases, while levels of endothelin-1 and platelet-derived growth factors increase, further promoting vasoconstriction and vascular remodeling.[1]

As pulmonary vascular resistance rises, pulmonary arterial pressure increases, elevating RV afterload. This increased workload leads to RV hypertrophy, dilation, or both.[1][6] The 2022 ESC/ERS guidelines now define pulmonary hypertension as mean pulmonary arterial pressure (mPAP) >20 mmHg at rest, with pre-capillary pulmonary hypertension characterized by pulmonary vascular resistance >2 Wood units and pulmonary arterial wedge pressure ≤15 mmHg.[8][9]

Progressive RV dysfunction can lead to elevated central venous pressure, hepatic congestion, and peripheral edema. In patients with COPD, peripheral edema development is often associated with hypercapnia. Additional mechanisms contributing to fluid retention include decreased glomerular filtration rate, reduced sodium excretion, and hypoxemia-stimulated arginine vasopressin release.[1][10]

Etiology

Common Causes:

• Chronic obstructive pulmonary disease (COPD) – most common cause, accounting for >50% of cases [2][4]
• Interstitial lung diseases (e.g., idiopathic pulmonary fibrosis) [11]
• Obstructive sleep apnea and obesity-hypoventilation syndrome [12]
• Chronic thromboembolic pulmonary hypertension [13]
• High altitude exposure (chronic mountain sickness) [1]
• Chest wall deformities (e.g., kyphoscoliosis) [1]
• Neuromuscular diseases affecting respiratory function [1]

Risk Factors

• Active or former cigarette smoking [5]
• Chronic hypoxia from any cause [7][14]
• Recurrent pulmonary emboli [13]
• Untreated or poorly controlled obstructive or restrictive lung disease [1]
• Poor treatment adherence in chronic lung conditions [1]
• Environmental and occupational exposures to pollutants [2]

Clinical Presentation #

History (Symptoms)

Early Symptoms:

• Exertional dyspnea – most common presenting symptom [1]
• Fatigue and generalized weakness [1]
• Reduced exercise tolerance [1]

Progressive Symptoms:

• Chest discomfort or pressure (reflecting RV strain) [1]
• Palpitations (secondary to arrhythmias) [1]
• Syncope or near-syncope, particularly with exertion [1]

Signs of Right Heart Failure:

• Peripheral edema (lower extremities) [1]
• Abdominal discomfort or fullness from hepatomegaly [1]
• Ascites [1]
• Weight gain from fluid retention [1]

Physical Examination Findings

Vital Signs:

• Tachypnea at rest or with minimal exertion [1]
• Hypoxemia (decreased oxygen saturation) [1]
• May demonstrate signs of pulmonary hypertension [1]

Cardiovascular Examination:

• Elevated jugular venous pressure (JVP) [1]
• Prominent jugular V wave (indicating tricuspid regurgitation) [1]
• Right ventricular heave or parasternal lift [1]
• Loud P2 (accentuated pulmonic component of second heart sound) [1]
• Holosystolic murmur of tricuspid regurgitation at left lower sternal border [1]
• Right-sided S3 or S4 gallop [1]

Pulmonary Examination:

• Signs of underlying lung disease (wheezing in COPD, crackles in ILD) [1]
• Cyanosis in advanced disease [1]

Abdominal Examination:

• Hepatomegaly [1]
• Hepatojugular reflux [1]
• Ascites [1]

Peripheral Examination:

• Pitting peripheral edema [1]
• Cool extremities (reflecting low cardiac output) [1]

Differential Diagnosis #

• Left-sided heart failure [1]
• Primary pulmonary arterial hypertension [1][8]
• Acute pulmonary embolism [1][13]
• Constrictive pericarditis [1]
• Liver cirrhosis with ascites and edema [1]
• Nephrotic syndrome [1]
• Venous insufficiency [1]

Diagnostic Testing #

Initial Diagnostic Studies

Electrocardiogram (ECG): [1]

• Right axis deviation
• Right ventricular hypertrophy
• R/S ratio >1 in lead V1
• P pulmonale (tall, peaked P waves in leads II, III, aVF)
• Right bundle branch block (in some cases)

Chest Radiography: [1]

• Enlargement of central pulmonary arteries
• RV enlargement (prominent cardiac silhouette)
• Signs of underlying lung pathology (hyperinflation in COPD, interstitial patterns in ILD)
• Peripheral pruning of pulmonary vasculature

Arterial Blood Gas (ABG): [14]

• Hypoxemia (PaO2 <60 mmHg)
• Hypercapnia (PaCO2 >45 mmHg) in advanced cases
• Respiratory acidosis or compensated respiratory acidosis

Advanced Diagnostic Testing

Echocardiography (Transthoracic): [1][8]

• RV dilation or hypertrophy
• Elevated RV systolic pressure (estimated from tricuspid regurgitation velocity)
• Septal flattening or paradoxical septal motion (D-shaped left ventricle)
• Estimation of pulmonary artery systolic pressure
• Tricuspid annular plane systolic excursion (TAPSE) for RV function assessment
• RV fractional area change

Pulmonary Function Tests (PFTs):[14]

• Assessment for obstructive pattern (COPD, asthma)
• Assessment for restrictive pattern (ILD, chest wall disorders)
• Diffusion capacity measurement

B-type Natriuretic Peptide (BNP) or NT-proBNP: [15]

• Elevated in RV dysfunction and heart failure
• Useful for prognostic assessment and monitoring

Right Heart Catheterization (Gold Standard): [1][8]

• Confirms pulmonary hypertension (mPAP >20 mmHg per 2022 ESC/ERS guidelines)
• Distinguishes pre-capillary from post-capillary pulmonary hypertension
• Measures pulmonary vascular resistance (>2 Wood units confirms pulmonary vascular disease)
• Excludes left heart disease as cause (PAWP ≤15 mmHg)
• Assesses cardiac output

Ventilation-Perfusion (V/Q) Scan or CT Pulmonary Angiography: [13]

• Evaluates for chronic thromboembolic disease
• Recommended in appropriate clinical contexts

Treatment #

Primary Treatment: Address Underlying Cause

Smoking Cessation: [16]

• Critical intervention for COPD-related cor pulmonale
• Counseling and pharmacotherapy (varenicline, bupropion, nicotine replacement)

Optimized Management of Lung Disease: [14][16]

• COPD: Bronchodilators (long-acting beta-agonists, long-acting muscarinic antagonists), inhaled corticosteroids, pulmonary rehabilitation
• Interstitial Lung Disease: Antifibrotic therapy where indicated, immunosuppression for inflammatory conditions
• Obstructive Sleep Apnea: Continuous positive airway pressure (CPAP) or bilevel positive airway pressure (BiPAP)

Long-Term Oxygen Therapy (LTOT): [17][18][19]

• Strong recommendation for patients with COPD and severe resting hypoxemia:
  • PaO2 ≤55 mmHg (7.3 kPa) or SpO2 ≤88%, OR
  • PaO2 56-59 mmHg (7.5-7.9 kPa) or SpO2 89% with evidence of cor pulmonale, pulmonary hypertension, or hematocrit ≥55%
• Prescribed for at least 15 hours per day, ideally 18-24 hours [17][18]
• Improves survival in severely hypoxemic COPD patients [18][20]
• May halt progression of or reverse pulmonary hypertension [19][21]
• Goal: Maintain PaO2 ≥60 mmHg or SpO2 ≥90% at rest [17]

Treatment of Infections: [1]

• Prompt treatment of respiratory infections
• Influenza and pneumococcal vaccination

Management of Right Heart Failure

Diuretics: [1][22]

• Loop diuretics (furosemide, torsemide) for peripheral edema and volume overload
• Caution: Over-diuresis can reduce RV preload and worsen cardiac output
• Monitor electrolytes and renal function closely

Pulmonary Vasodilators: [8][22][23]

• Limited evidence in Group 3 PH (lung disease-associated):
  • Current evidence does NOT support routine use of pulmonary vasodilators in COPD-associated pulmonary hypertension [22][23]
  • 2022 ESC/ERS guidelines: Phosphodiesterase-5 inhibitors (PDE5i) may be considered in severe PH associated with ILD, with individual decision-making in specialized PH centers [8]
  • Not recommended for routine use in COPD-related cor pulmonale [23][24]
• Approved for Group 1 PAH and Group 4 CTEPH only:
  • PDE5 inhibitors (sildenafil, tadalafil)
  • Endothelin receptor antagonists (bosentan, ambrisentan, macitentan)
  • Prostacyclin analogs (epoprostenol, treprostinil, iloprost)
  • Soluble guanylate cyclase stimulators (riociguat)
  • Prostacyclin receptor agonist (selexipag)

Digoxin:[1][22]

• Limited evidence for benefit in isolated RV failure
• May be considered if concomitant left ventricular dysfunction
• Use with caution due to increased sensitivity in COPD patients

Anticoagulation:[1]

• Indicated for chronic thromboembolic pulmonary hypertension
• May be considered in patients with significant risk factors for venous thromboembolism
• Individual risk-benefit assessment required

Supportive and Lifestyle Measures

Dietary Modifications: [1]

• Sodium restriction to minimize fluid retention

Exercise and Rehabilitation: [16]

• Pulmonary rehabilitation programs
• Supervised, individualized exercise programs
• Improves functional capacity and quality of life

Vaccinations: [25][26]

• Influenza: Annual vaccination recommended for all adults ≥50 years [26]
• Pneumococcal: CDC recommends for all adults ≥50 years (as of October 2024) [25]
  • PCV20 or PCV21 (single dose) OR
  • PCV15 followed by PPSV23 one year later (minimum 8 weeks)
• COVID-19: Per current CDC guidelines

Avoidance of Respiratory Depressants: [1]

• Limit or avoid opioids, benzodiazepines, and other respiratory depressants
• Caution with sedating medications

High Altitude Avoidance:[1]

• Avoid high-altitude locations that may worsen hypoxemia

Patient Education, Counseling, Screening, and Vaccines #

Patient Education

Oxygen Therapy Education: [17]

• Proper use and maintenance of oxygen equipment
• Fire safety precautions (no smoking around oxygen)
• Importance of adherence to prescribed oxygen flow rate and duration
• Recognition of equipment malfunction

Disease Management: [1]

• Recognition of worsening symptoms (increased dyspnea, edema, weight gain)
• Importance of medication adherence
• Proper inhaler technique
• Self-monitoring strategies

Lifestyle Modifications: [16]

• Smoking cessation counseling and resources
• Dietary sodium restriction
• Maintaining physical activity as tolerated
• Importance of pulmonary rehabilitation

Screening Recommendations (USPSTF)

Lung Cancer Screening: [27][28]

• Population: Adults aged 50-80 years with 20 pack-year smoking history who currently smoke or have quit within the past 15 years
• Method: Annual low-dose computed tomography (LDCT)
• Grade: B recommendation
• Implementation: Should involve shared decision-making discussing benefits, limitations, and harms

Vaccination Recommendations

CDC/ACIP Guidelines: [25][26]

Influenza Vaccine:

• Annual vaccination recommended for all adults, particularly those with chronic lung disease

Pneumococcal Vaccine (Updated October 2024):

• All adults ≥50 years: One dose of PCV20 or PCV21 (pneumococcal vaccination complete), OR PCV15 followed by PPSV23 one year later (minimum interval 8 weeks)

COVID-19 Vaccine:

• Updated vaccines per current CDC recommendations

Tdap/Td:

• Tetanus, diphtheria, pertussis booster per routine schedule

Note: The USPSTF refers immunization recommendations to the CDC Advisory Committee on Immunization Practices (ACIP) for evidence-based guidance. [29]

Mental Health Screening

Depression Screening: [1]

• Chronic lung disease associated with increased depression risk
• Routine screening recommended
• Referral to mental health services when indicated

Specialty Consultations #

Pulmonology: [1]

• Comprehensive workup and management of underlying lung disease
• Pulmonary function testing interpretation
• Consideration for advanced therapies

Cardiology: [8]

• Assessment and management of RV dysfunction
• Echocardiographic evaluation and interpretation
• Risk stratification
• Consideration for advanced heart failure therapies if indicated

Sleep Medicine: [1]

• Evaluation and management of suspected sleep-disordered breathing
• Polysomnography when indicated
• Initiation and titration of positive airway pressure therapy

Social Work: [1]

• Assistance with home oxygen equipment procurement
• Connection to community resources
• Support with medication access and affordability
• Home care coordination

Palliative Care: [1]

• Symptom management in advanced disease
• Goals of care discussions
• End-of-life planning for patients with poor prognosis

Follow-Up and Monitoring #

Initial Follow-Up (3 months): [17]

• Reassess need for LTOT (if prescribed)
• Evaluate symptom control
• Review medication adherence and technique
• Assess for complications

Regular Follow-Up (6-12 months): [17]

• Monitor symptoms and functional status
• Oxygen saturation monitoring
• Weight and volume status assessment
• Reassess RV function and pulmonary pressures via echocardiography as clinically indicated
• Monitor renal function and electrolytes (if on diuretics)
• Evaluate adherence to therapies
• Adjust treatment based on underlying disease progression
• Update advance care planning

Close Monitoring Situations: [1]

• Recent hospitalization
• Medication changes
• Worsening symptoms
• Development of new comorbidities

Prognosis #

The prognosis of cor pulmonale varies significantly based on the underlying etiology. In COPD patients who develop cor pulmonale, approximately 30% survive 5 years, though whether cor pulmonale carries independent prognostic value beyond reflecting disease severity remains unclear.[4] The development of clinical right heart failure (peripheral edema) historically indicated poor prognosis, though with LTOT implementation, prolonged survival (≥10 years) can be observed after the first episode of peripheral edema.[30] For acute cor pulmonale in ARDS, presence of cor pulmonale is an independent risk factor for 28-day mortality.[3]

References #

1. Budev MM, Arroliga AC, Wiedemann HP, Matthay RA. Cor pulmonale: an overview. Semin Respir Crit Care Med. 2003 Jun;24(3):233-44. https://doi.org/10.1055/s-2003-42371

2. Weitzenblum E, Chaouat A. Cor pulmonale. Chron Respir Dis. 2009;6(3):177-185. https://doi.org/10.1177/1479972309104664

3. Vieillard-Baron A, Schmitt JM, Augarde R, et al. Acute cor pulmonale in acute respiratory distress syndrome submitted to protective ventilation: incidence, clinical implications, and prognosis. Crit Care Med. 2001;29(8):1551-1555. https://doi.org/10.1097/00003246-200108000-00009

4. Kessler R, Faller M, Weitzenblum E, et al. “Natural history” of pulmonary hypertension in a series of 131 patients with chronic obstructive lung disease. Am J Respir Crit Care Med. 2001;164(2):219-224. https://doi.org/10.1164/ajrccm.164.2.2006129

5. Celli BR, Wedzicha JA. Update on clinical aspects of chronic obstructive pulmonary disease. N Engl J Med. 2019;381(13):1257-1266. https://doi.org/10.1056/NEJMra1900500

6. Voelkel NF, Quaife RA, Leinwand LA, et al. Right ventricular function and failure: report of a National Heart, Lung, and Blood Institute working group on cellular and molecular mechanisms of right heart failure. Circulation. 2006;114(17):1883-1891. https://doi.org/10.1161/CIRCULATIONAHA.106.632208

7. Sylvester JT, Shimoda LA, Aaronson PI, Ward JP. Hypoxic pulmonary vasoconstriction. Physiol Rev. 2012;92(1):367-520. https://doi.org/10.1152/physrev.00041.2010

8. Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022;43(38):3618-3731. https://doi.org/10.1093/eurheartj/ehac237

9. Rosenkranz S, Delcroix M, Giannakoulas G, et al. The ‘Ten Commandments’ of the 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2023;44(10):792-793. https://doi.org/10.1093/eurheartj/ehad018

10. MacNee W. Pathophysiology of cor pulmonale in chronic obstructive pulmonary disease. Part One. Am J Respir Crit Care Med. 1994;150(3):833-852. https://doi.org/10.1164/ajrccm.150.3.8087662

11. Raghu G, Remy-Jardin M, Myers JL, et al. Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2018;198(5):e44-e68. https://doi.org/10.1164/rccm.201807-1255ST

12. Mokhlesi B, Tulaimat A. Recent advances in obesity hypoventilation syndrome. Chest. 2007;132(4):1322-1336. https://doi.org/10.1378/chest.07-0027

13. Delcroix M, Torbicki A, Gopalan D, et al. ERS statement on chronic thromboembolic pulmonary hypertension. Eur Respir J. 2021;57(6):2002828. https://doi.org/10.1183/13993003.02828-2020

14. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (2024 Report). Available at: https://goldcopd.org

15. Fijalkowska A, Kurzyna M, Torbicki A, et al. Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension. Chest. 2006;129(5):1313-1321. https://doi.org/10.1378/chest.129.5.1313

16. Spruit MA, Singh SJ, Garvey C, et al. An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care Med. 2013;188(e13):e13-e64. https://doi.org/10.1164/rccm.201309-1634ST

17. Croxton TL, Bailey WC. Long-term oxygen treatment in chronic obstructive pulmonary disease: recommendations for future research: an NHLBI workshop report. Am J Respir Crit Care Med. 2006;174(4):373-378. https://doi.org/10.1164/rccm.200507-1161WS

18. Lacasse Y, Tan AM, Maltais F, Goldstein RS. Home oxygen in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2018;197(10):1254-1264. https://doi.org/10.1164/rccm.201802-0382CI

19. Weitzenblum E, Sautegeau A, Ehrhart M, Mammosser M, Pelletier A. Long-term oxygen therapy can reverse the progression of pulmonary hypertension in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis. 1985;131(4):493-498. https://doi.org/10.1164/arrd.1985.131.4.493

20. Hess MW. Oxygen Therapy in COPD. Respir Care. 2023;68(7):998-1012. https://doi.org/10.4187/respcare.10876

21. Zieliński J, Tobiasz M, Hawryłkiewicz I, Śliwiński P, Pałasiewicz G. Effects of long-term oxygen therapy on pulmonary hemodynamics in COPD patients. A 6-year prospective study. Chest. 1998;113(1):65-70. https://doi.org/10.1378/chest.113.1.65

22. Klinger JR, Hill NS. Right ventricular dysfunction in chronic obstructive pulmonary disease. Evaluation and management. Chest. 1991;99(3):715-723. https://doi.org/10.1378/chest.99.3.715

23. Arrigo M, Price S, Harjola VP, et al. Diagnosis and treatment of right ventricular failure secondary to acutely increased right ventricular afterload (acute cor pulmonale): a clinical consensus statement of the Association for Acute CardioVascular Care of the European Society of Cardiology. Eur Heart J Acute Cardiovasc Care. 2024;13(3):304-312. https://doi.org/10.1093/ehjacc/zuad157

24. Stolz D, Rasch H, Linka A, et al. A randomised, controlled trial of bosentan in severe COPD. Eur Respir J. 2008;32(3):619-628. https://doi.org/10.1183/09031936.00011308

25. Centers for Disease Control and Prevention. Pneumococcal Vaccine Recommendations. Updated October 26, 2024. Available at: https://www.cdc.gov/pneumococcal/hcp/vaccine-recommendations/index.html

26. Grohskopf LA, Blanton LH, Ferdinands JM, et al. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices — United States, 2024–25 Influenza Season. MMWR Recomm Rep. 2024;73(5):1-25. https://doi.org/10.15585/mmwr.rr7305a1

27. US Preventive Services Task Force. Screening for Lung Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2021;325(10):962-970. https://doi.org/10.1001/jama.2021.1117

28. Jonas DE, Reuland DS, Reddy SM, et al. Screening for Lung Cancer With Low-Dose Computed Tomography: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2021;325(10):971-987. https://doi.org/10.1001/jama.2021.0377

29. US Preventive Services Task Force. A and B Recommendations. Available at: https://doi.org/10.17226/13181

30. Weitzenblum E, Apprill M, Oswald M, Chaouat A, Imbs JL. Pulmonary hemodynamics in patients with chronic obstructive pulmonary disease before and during an episode of peripheral edema. Chest. 1994;105(5):1377-1382. https://doi.org/10.1378/chest.105.5.1377

#